NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell that participates in cellular energy metabolism and redox reactions. In compounding, NAD+ refers to preparations of the coenzyme dispensed by licensed pharmacies for provider-administered or provider-prescribed use, most commonly in intravenous, subcutaneous, and intranasal forms.
Compounded NAD+ ranks as the #7 most-prescribed compounded product on ScriptLinkRx, based on cumulative order volume across clinics ordering through the platform as of mid-2026. It sits within the longevity and wellness category alongside peptides and antioxidant preparations, and it carries regulatory and sourcing considerations that differ meaningfully from FDA-approved medications.
What NAD+ Is
NAD+ is a dinucleotide coenzyme present in all cells. It exists in two interconvertible states — the oxidized form (NAD+) and the reduced form (NADH) — and functions as an electron carrier in the reactions that convert nutrients into cellular energy. It also serves as a substrate for several classes of enzymes, including sirtuins and PARPs, that participate in cellular signaling and DNA-repair pathways.
Cells synthesize NAD+ from dietary precursors, including niacin (vitamin B3) and related compounds such as nicotinamide riboside and nicotinamide mononucleotide. Because NAD+ is an endogenous molecule rather than a novel chemical entity, it is frequently discussed in the same context as vitamins and cofactors. That classification, however, does not exempt injectable or otherwise parenteral NAD+ preparations from the regulatory and quality standards that apply to compounded sterile drugs. As of July 2026, NAD+ is not an FDA-approved drug, and compounded NAD+ preparations have not been reviewed by the FDA for safety, effectiveness, or quality.
How Providers Use It in Practice
NAD+ preparations are ordered predominantly by longevity, wellness, and integrative-medicine practices, and they also appear in the offerings of some med spas and concierge clinics. Providers describe using NAD+ in the general context of metabolic and cellular-health programs, often as part of a broader menu that may include vitamin infusions, antioxidant preparations, and peptides.
The verbs matter here. Some clinics offer NAD+ infusions or injections as an elective wellness service; providers order it, administer it, or prescribe it for at-home use depending on the dosage form and their state's scope-of-practice rules. This article describes the practice context in which NAD+ is ordered — it does not assert clinical outcomes. NAD+ has not been demonstrated in FDA review to produce anti-aging, cognitive, or metabolic benefits, and providers considering it should form their own clinical judgment about individual patient appropriateness and informed consent, particularly given the elective, non-approved nature of the preparation.
Forms and Combinations Available Through Compounding
Compounding exists for NAD+ because no FDA-approved NAD+ drug product is available, and because the coenzyme is dispensed in several routes and concentrations that a single manufactured product would not accommodate. Compounding pharmacies prepare NAD+ to a prescriber's specifications for an identified patient.
Dosage forms ordered through compounding pharmacies commonly include:
- Intravenous (IV) solutions — typically administered in a clinical setting under supervision.
- Subcutaneous injections — sometimes dispensed as multi-dose vials for provider-directed use.
- Intranasal sprays — a non-injectable route some clinics offer.
- Troches or sublingual preparations — oral-mucosal forms used by some practices.
NAD+ is also compounded in combination preparations. It appears alongside other agents in some metabolic and wellness formulations — for example, in combination products that pair NAD+ with GLP-1 receptor agonists and amino acids such as L-carnitine. When NAD+ is added to another compounded medication, the individualized clinical rationale for the combination is the prescriber's responsibility to document; the FDA has questioned blanket clinical justifications for additive combinations, and a patient-specific need should support each ordered formulation rather than a marketing-driven default. This page does not provide strengths, concentrations, volumes, or administration schedules; those are determined by the prescriber and pharmacy for the individual patient.
Regulatory Status and Provider Considerations
As of July 2026, the regulatory picture for compounded NAD+ centers on three facts that providers should weigh.
NAD+ is not FDA-approved. There is no FDA-approved NAD+ drug product. Compounded preparations, including NAD+, are not reviewed by the FDA for safety, effectiveness, or quality before they are dispensed, and they are not equivalent to FDA-approved drugs. Compounded drugs carry a higher baseline risk profile than approved products for that reason.
Ingredient grade is a documented safety concern. In an October 2024 statement, the FDA reminded compounders to use ingredients suitable for sterile compounding and specifically noted awareness of compounders using food-grade NAD+ sold by repackagers to make intravenous products. The FDA stated that ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing, because of the high risk of contamination with microbes and endotoxins. The agency also reported receiving adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting, and fatigue, with some cases requiring medical treatment.
Sterile-compounding quality is the key variable. Because parenteral NAD+ is a sterile preparation made from a non-approved bulk substance, the quality of the API, the grade of the raw material, and the pharmacy's sterile-compounding controls are the primary determinants of the preparation's risk profile. Providers ordering NAD+ should confirm that the pharmacy is not using food-grade or dietary-supplement-grade material and that it applies pharmaceutical-grade ingredients and validated sterile processes.
Clinics that order compounded medications do so through licensed compounding pharmacies, and platforms like ScriptLinkRx connect providers with licensed partner pharmacies for that purpose. The regulatory responsibility for a valid prescription, patient-specific need, and appropriate use remains with the prescriber.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Given the FDA's specific concerns about NAD+ ingredient grade and sterility, provider due diligence around sourcing is especially warranted. Consider asking a prospective compounding pharmacy:
- API source and grade. Is the NAD+ pharmaceutical-grade rather than food-grade or supplement-grade? Can the pharmacy provide the supplier name and a Certificate of Analysis (COA) for each lot?
- Certificates of Analysis. Does each batch come with documentation of identity, potency, and purity?
- USP compliance. Does the pharmacy follow USP <795> (non-sterile compounding), USP <797> (sterile compounding), and USP <800> (hazardous drugs) where applicable? Parenteral NAD+ falls under sterile-compounding standards.
- Sterility and endotoxin testing. For injectable and IV preparations, does the pharmacy perform or contract sterility testing and bacterial endotoxin testing? Endotoxin contamination has been a documented issue with NAD+ preparations.
- Potency testing. Is finished-preparation potency verified, and by what method?
- Beyond-use dating (BUD). How is BUD assigned for each dosage form, and is it consistent with USP standards and the pharmacy's stability data?
- State licensure and inspection history. Is the pharmacy licensed in the states where it ships, and is it a 503A pharmacy or 503B outsourcing facility? What is its inspection and recall history?
A pharmacy that can readily produce COAs, sterility and endotoxin data, and clear documentation of ingredient grade is demonstrating the controls that the FDA's guidance emphasizes for this preparation.
Frequently Asked Questions
Is compounded NAD+ FDA-approved?
No. As of July 2026 there is no FDA-approved NAD+ drug product, and compounded NAD+ preparations are not reviewed by the FDA for safety, effectiveness, or quality. Compounded NAD+ is not equivalent to an FDA-approved medication.
What is the main quality risk with compounded NAD+?
Ingredient grade and sterility. The FDA has specifically flagged compounders using food-grade NAD+ to make injectable products and has noted contamination risks from microbes and endotoxins, along with adverse event reports following use of NAD+ injectables. Pharmaceutical-grade API and validated sterile-compounding processes are the central safeguards.
What forms is NAD+ available in through compounding?
Compounding pharmacies commonly prepare NAD+ as intravenous solutions, subcutaneous injections, intranasal sprays, and oral-mucosal troches or sublingual preparations, as well as in some combination formulations. The route and formulation are specified by the prescriber for an individual patient.
Which specialties order compounded NAD+?
Longevity, wellness, integrative-medicine, concierge, and some med-spa practices order NAD+ preparations, typically as part of elective metabolic- and cellular-health service menus.
Can NAD+ be combined with other compounded agents?
It is sometimes compounded in combination with other agents, including certain GLP-1 and amino-acid formulations. When NAD+ is added to another preparation, the prescriber is responsible for documenting the patient-specific clinical rationale for the combination, since the FDA has questioned blanket justifications for additive combinations.
Related Reading
- See where NAD+ ranks among the most-prescribed compounded medications
- 5-Amino-1MQ for clinics
- Compounded glutathione: forms and sourcing
- Compounded tirzepatide with NAD+ and L-carnitine
